Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals
2015 ASH Annual MeetingJulie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).
Related Videos
John Leonard, MD, on DLBCL: Results From the Pyramid Trial
John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like su...
David Henry, MD, on Anticoagulants: Expert Perspective
David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.
James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial
James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimer...
Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine
Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating age...
Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial
Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adap...
